Thierry L. Bernard was appointed Director of Bruker Corp, effective April 1, 2026. As of November 6, 2026, Bruker Corp has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 1, 2026 to April 10, 2026, naming 1 appointment and 1 departure (Form 8-K, April 1, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Bruker Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Bruker Corp reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-01 to 2026-04-10. They name 1 person, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Bruker Corp files it.
Also on the record for Bruker Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 15% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by ORBIS INVESTMENT MANAGEMENT LTD | 11.1% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 12.4% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 6, 2026 | Stake report, Schedule 13G/A, by ORBIS INVESTMENT MANAGEMENT LTD | 10% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by ORBIS INVESTMENT MANAGEMENT LTD | 9.3% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 3% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by ORBIS INVESTMENT MANAGEMENT LTD | 8.8% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 5.1% of the class | 5%+ stakes | Source |
| October 7, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 11% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 7.5% of the class | 5%+ stakes | Source |
| August 6, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 5.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Bruker Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on Bruker Corp and the records around it.
Bruker Corp elsewhere on the record
Companies that share a holder
- ORBIS INVESTMENT MANAGEMENT LTD also filed stake reports on 23 other companies: RXO, Inc. (Nov 2026), National CineMedia, Inc. (Sep 2026), BBB FOODS INC (Aug 2026)
- T. Rowe Price Investment Management, Inc. also filed stake reports on 167 other companies: CABALETTA BIO INC (Nov 2026), MADISON SQUARE GARDEN SPORTS CORP (Nov 2026), MSG RANGERS CORP (Nov 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Bruker Corp
Get an email when Bruker Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Bruker Corp?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Bruker Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bruker Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-10 | Reported | not named in the filing | 8-K, 2026-04-10 | ||
| 2026-04-01 | In | Director | 2026-04-01 | 8-K, 2026-04-01 | |
| 2026-04-01 | Out | 8-K, 2026-04-01 |
Who leads Bruker Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Thierry L. Bernard, appointed, effective 2026-04-01 (filed 2026-04-01).
New leaders reset buying decisions — get the Full Report on Bruker Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Bruker Corp, with the record behind each one.
Find candidates like Director at Bruker CorpEvery change, in the filing's words
Reported
On April 6, 2026, Bruker Corporation (the "Company") and Falko Busse, Ph.D., an executive officer of the Company and President of the Bruker BioSpin Group ("Bruker BioSpin"), a wholly owned subsidiary of the Company, agreed that his duties as executive officer with the Company and as President of Bruker BioSpin would transition on or around May 1, 2026 and that his employment with the Company and Bruker BioSpin would terminate as of October 31, 2026 (the "Separation Date").
- In connection with Dr. Busse's departure, Bruker Switzerland AG and Dr. Busse entered into a mutual separation agreement (the "Separation Agreement"), dated as of April 7, 2026.
- The Separation Agreement provides for separation benefits including severance, pro-rated bonus, and a payout for unused vacation days in an aggregate amount of CHF equal to approximately $1,020,351 to be paid upon the Separation Date.
- In addition, consistent with the provisions of the applicable plans and award agreements, Dr. Busse shall forfeit any unvested equity awards that he may hold on the Separation Date.
- The Separation Agreement also contains customary provisions, including restrictive covenants and confidentiality, non-solicitation, and non-disparagement obligations.
Appointed: Thierry L. Bernard, Director, effective 2026-04-01
(d) Election of New Director On March 27, 2026, the Board of Directors (the "Board") of Bruker Corporation (the "Company") approved an increase in the number of directors to expand the size of the Board by one director to a total of twelve directors, with such additional director assigned to Class III, and appointed Thierry L. Bernard to fill the newly created vacancy on the Board, effective as of April 1, 2026.
Departing: Thierry L. Bernard
In November 2025, QIAGEN announced a CEO transition plan whereby Mr. Bernard will step down as CEO and Managing Director once his successor is appointed.
- Mr. Bernard will initially serve as a director until the 2027 Annual Meeting of Stockholders.
- Mr. Bernard currently serves as Chief Executive Officer ("CEO") and Managing Director of QIAGEN N.V. (NYSE: QGEN) ("QIAGEN").
- Mr. Bernard joined QIAGEN in February 2015 to lead its growing molecular diagnostics business and was named Chief Executive Officer in March 2020 after serving in this role on an interim basis since October 2019 and became a member of its managing board in 2021.
- Previously, he held roles of increasing responsibility during 15 years with bioM rieux SA, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region.
- He also held senior management roles in several other leading international companies.
- In March 2023, he was named Chair of the AdvaMedDx Board of Directors, a U.S. industry trade association, and joined the board of directors of Neogen Corporation (NASDAQ: NEOG) in 2024.
- Mr. Bernard has earned degrees and certifications from Sciences Po, LSE, the College of Europe, Harvard Business School, Centro de Comercio Exterior de Barcelona and has been appointed Conseiller du Commerce Ext rieur by the French government.
Tools for this story
Each opens in a new tab, filled in for Bruker Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.